In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods

M A Pfaller; L Boyken; R J Hollis; S A Messer; S Tendolkar; D J Diekema

doi:10.1128/JCM.43.8.3807-3810.2005

Back

In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods

Journal article

Open access

Peer reviewed

In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods

M A Pfaller, L Boyken, R J Hollis, S A Messer, S Tendolkar and D J Diekema

Journal of clinical microbiology, Vol.43(8), pp.3807-3810

08/2005

DOI: 10.1128/JCM.43.8.3807-3810.2005

PMCID: PMC1233954

PMID: 16081915

Files and links (1)

url

https://doi.org/10.1128/JCM.43.8.3807-3810.2005View

Published (Version of record) Open Access

Abstract

The in vitro activity of itraconazole was determined against 7,299 isolates of Candida spp., 1,615 isolates of Cryptococcus neoformans, and 445 isolates of Aspergillus spp. obtained from over 200 medical centers worldwide. Itraconazole was active against all Candida spp. (96% of MICs were < or =1 microg/ml) with the exception of C. glabrata (77% of MICs were < or =1 microg/ml). Itraconazole inhibited 94% of C. krusei and 84% of other fluconazole-resistant Candida species, exclusive of C. glabrata, at a MIC of < or =1 microg/ml. Itraconazole was not active against fluconazole-resistant isolates of C. glabrata. Only modest activity was seen against C. neoformans (80% of MICs were < or =1 microg/ml); however, itraconazole showed excellent activity against Aspergillus spp. (94% of MICs were < or =1 microg/ml). These results provide an update on the antifungal activity of itraconazole against major opportunistic fungal pathogens. In light of the new intravenous formulation of itraconazole these data suggest that this agent remains a viable systemically active antifungal agent.

Antifungal Agents - pharmacology

Microbial Sensitivity Tests - standards

Humans

Candida - drug effects

Drug Resistance, Fungal

Microbial Sensitivity Tests - methods

Itraconazole - pharmacology

Aspergillus - drug effects

Cryptococcus neoformans - drug effects

Details

Title: Subtitle: In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods
Creators: M A Pfaller - Department of Pathology, Medical Microbiology Division, C606 GH, University of Iowa College of Medicine, Iowa City, IA 52242, USA. michael-pfaller@uiowa.edu
L Boyken
R J Hollis
S A Messer
S Tendolkar
D J Diekema
Resource Type: Journal article
Publication Details: Journal of clinical microbiology, Vol.43(8), pp.3807-3810
DOI: 10.1128/JCM.43.8.3807-3810.2005
PMID: 16081915
PMCID: PMC1233954
NLM abbreviation: J Clin Microbiol
ISSN: 0095-1137
eISSN: 1098-660X
Publisher: United States
Language: English
Date published: 08/2005
Academic Unit: Infectious Diseases; Epidemiology; Pathology; Internal Medicine
Record Identifier: 9983986260702771

Metrics

17 Record Views

58 Times Cited - Web of Science